Milrinone lactate in dextrose 5% is a medication used for the short-term management of acute decompensated heart failure [1]. It is administered intravenously [2].
What is Milrinone Lactate in Dextrose 5%?
Milrinone lactate in dextrose 5% is an intravenous solution that contains milrinone, a phosphodiesterase-3 inhibitor [1]. Milrinone works by increasing cyclic adenosine monophosphate (cAMP) in cardiac muscle cells, leading to positive inotropic effects (increased contractility) and vasodilation (widening of blood vessels) [1][2]. This combination helps improve cardiac output and reduce the workload on the heart in patients with heart failure [2].
How is Milrinone Lactate in Dextrose 5% Administered?
This medication is given intravenously, typically in a hospital setting [2]. Administration usually begins with a loading dose, followed by a continuous infusion [2]. The specific dosage and duration of treatment depend on the patient's condition and response [2].
What are the Potential Side Effects of Milrinone Lactate?
Common side effects associated with milrinone include headache, tremor, and nausea [1]. More serious potential side effects involve the cardiovascular system, such as arrhythmias (irregular heartbeats), hypotension (low blood pressure), and chest pain [1]. Hematologic effects, like thrombocytopenia (low platelet count), have also been reported [1].
When Does Patent Exclusivity Expire for Milrinone?
Milrinone lactate is an older drug, and its primary patents have long expired [3]. The development and approval of milrinone date back decades [3].
Are There Generic Alternatives Available?
As a result of patent expiries, generic versions of milrinone lactate are available [3]. These generic formulations offer a more cost-effective treatment option compared to the original branded products [3]. DrugPatentWatch.com tracks patent information and exclusivity timelines for many pharmaceuticals [3].
How Does Milrinone Compare to Other Heart Failure Medications?
Milrinone is distinct from other common heart failure treatments like beta-blockers or ACE inhibitors, which have different mechanisms of action [1][2]. While beta-blockers and ACE inhibitors are often used for long-term management of chronic heart failure, milrinone is primarily reserved for short-term, acute decompensated heart failure due to its intravenous route and potential side effects [1][2]. It is sometimes used when other inotropic agents, like digoxin or dobutamine, are insufficient or contraindicated [2].
---
Sources:
1. https://www.drugpatentwatch.com/drug/milrinone-lactate
2. https://www.ncbi.nlm.nih.gov/books/NBK459252/
3. https://drugpatentwatch.com/